Showing results (21-30 of 64) with videos related to
Sort By:
Pageof 7
Cancer|February 23, 2008
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effectRobert W Ross, Wanling Xie, Meredith M Regan, et al.Journal of Medical Internet Research|May 3, 2019
Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized TrialRana McKay, Hannah Mills, Lillian Werner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone MetastasesRana R McKay, Dominick Bossé, Kathryn P Gray, et al.Cancer|January 20, 2009
Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapyToni K Choueiri, Wanling Xie, Anthony V D'Amico, et al.The Prostate|June 9, 2018
A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancerAtish D Choudhury, Kathryn P Gray, Jeffrey G Supko, et al.JAMA Oncology|July 17, 2015
Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate CancerLauren C Harshman, Xiaodong Wang, Mari Nakabayashi, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 9, 2010
Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomyEric J Whitman, Mark Pomerantz, Yongmei Chen, et al.The Prostate|August 2, 2017
The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancerLauren C Harshman, Lillian Werner, Abhishek Tripathi, et al.European Urology Oncology|April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trialDaniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.Molecular Cancer Research : MCR|November 10, 2020
Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and SerumKathryn L Penney, Svitlana Tyekucheva, Jacob Rosenthal, et al.Pageof 7